Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
News & Press: Industry News

Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out

Wednesday, August 27, 2014   (0 Comments)
Posted by: Megan Jeffrey
Share |
Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out | Puget Sound Business Journal 

more Calendar

9/26/2017
2017 LSW Program: Cancer Immunotherapy

Featured Partners
BioTech Primer Inc.BioTech Primer develops and delivers customized training to the Life Sciences community

Membership Management Software Powered by YourMembership  ::  Legal